Kiniksa Pharmaceuticals Interna (KNSA) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $52.30, A.R:R 0.5:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ARCALYST; Concentration risk — Supplier: Regeneron.
Kiniksa Pharmaceuticals commercializes ARCALYST (rilonacept), an FDA-approved IL-1α/β inhibitor for recurrent pericarditis, as its sole commercial product in the United States, from which it derives substantially all revenue; profits on sales are evenly split with licensor... Read more
Sell if holding. At $52.30, A.R:R 0.5:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ARCALYST; Concentration risk — Supplier: Regeneron. Chart setup: Golden cross, above all MAs, RSI 52, MACD bullish. Score 6.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 42d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Kiniksa Pharmaceuticals Interna
About Kiniksa Pharmaceuticals Interna
ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis, generates substantially all of Kiniksa Pharmaceuticals' revenue, with the United States as the sole authorized market for commercial sale. FDA approved ARCALYST for recurrent pericarditis in March 2021 for adults and children 12 years and older; Kiniksa estimates the U.S. prevalent patient population at approximately 40,000. In October 2025, pipeline candidate KPL-387 received Orphan Drug Designation from the FDA for the treatment of pericarditis.
Kiniksa sells ARCALYST through a select network of specialty pharmacies, with profits on U.S. sales and third-party proceeds evenly split with Regeneron under the 2017 license agreement. Regeneron currently manufactures and supplies all requirements for both development and commercial use under a Supply Agreement, though a technology transfer to Samsung as replacement drug substance manufacturer is underway. The company's commercial focus targets approximately 14,000 patients with persistent disease and multiple recurrences as a core population, while also expanding reach to a broader first-recurrence cohort of roughly 26,000 additional patients. In 2022, Kiniksa granted Huadong exclusive rights to develop and commercialize ARCALYST in the Asia Pacific region excluding Japan. Clinical-stage asset KPL-387, an IL-1R1 inhibitor designed for monthly subcutaneous dosing, entered Phase 2/3 trials in recurrent pericarditis in July 2025, with Phase 2 data expected in the second half of 2026.
Show full overview
Regeneron serves as the sole manufacturer of ARCALYST drug substance and commercial supply until completion of the Samsung technology transfer. A disruption at Regeneron or a delay in the Samsung qualification process could interrupt commercial supply of Kiniksa's only revenue-generating product. The 10-K specifically identifies delays in the technology transfer as a factor that could materially affect commercialization. Pre-revenue pipeline asset KPL-1161 is targeted for a Phase 1 first-in-human trial by end of 2026, but the company has no alternative commercial revenue source if ARCALYST supply were disrupted.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Kiniksa Pharmaceuticals Interna's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-17Recent Developments — Kiniksa Pharmaceuticals Interna
Latest news
- NEWS Kiniksa Pharmaceuticals International (KNSA) Reports Q1 2026 Numbers - AlphaStreet — AlphaStreet neutral
- NEWS Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat — MarketBeat positive
- NEWS KNSA Expects Higher Revenue Projections for ARCALYST in 2026 - GuruFocus — GuruFocus positive
- NEWS KNSA Earnings: Kiniksa Pharmaceuticals Stock Surges on Strong Q1 Beats - TipRanks — TipRanks positive
- NEWS Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-17T09:07:23Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductARCALYST10-K Item 1A: 'ARCALYST, our sole product, for the treatment of recurrent pericarditis in the United States, where we derive substantially all of our revenue'
- HIGHSupplierRegeneron10-K Item 1: 'Regeneron currently manufactures and supplies all of our requirements of ARCALYST for development and commercial activities'
- HIGHGeographicUnited States10-K Item 1A: 'the United States, where we derive substantially all of our revenue'
Material Events(8-K, last 90d)
- 2026-05-01Item 5.02LOWChief Strategy Officer Eben Tessari resigned effective May 15, 2026, to pursue another executive position in life sciences. Will become consultant and advisor to Science and Research Committee. No disagreement with company operations, policies, or practices cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $52.30, A.R:R 0.5:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ARCALYST; Concentration risk — Supplier: Regeneron. Chart setup: Golden cross, above all MAs, RSI 52, MACD bullish. Prior stop was $48.64. Score 6.5/10, moderate confidence.
Take-profit target: $55.24 (+5.6% upside). Prior stop was $48.64. Stop-loss: $48.64.
Concentration risk — Product: ARCALYST; Concentration risk — Supplier: Regeneron; Thin upside margin: 5.6%.
Kiniksa Pharmaceuticals Interna trades at a P/E of 57.5 (forward 29.8). TrendMatrix value score: 5.2/10. Verdict: Sell.
14 analysts cover KNSA with a consensus score of 4.3/5. Average price target: $64.
What does Kiniksa Pharmaceuticals Interna do?Kiniksa Pharmaceuticals commercializes ARCALYST (rilonacept), an FDA-approved IL-1α/β inhibitor for recurrent...
Kiniksa Pharmaceuticals commercializes ARCALYST (rilonacept), an FDA-approved IL-1α/β inhibitor for recurrent pericarditis, as its sole commercial product in the United States, from which it derives substantially all revenue; profits on sales are evenly split with licensor Regeneron. The company also has KPL-387 in Phase 2/3 development for the same indication, with Phase 2 data expected in the second half of 2026.